Further characterization of antagonism by alpha(2)-adrenoceptor agonists of contractions induced by alpha(1)-adrenoceptor agonists

被引:0
|
作者
Nomura, S [1 ]
Sunagane, N [1 ]
Uruno, T [1 ]
Kubota, K [1 ]
机构
[1] SCI UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHARMACOL,TOKYO 162,JAPAN
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The population of alpha(2)-adrenoceptor subtypes functionally mediating contraction in response to phenylephrine was examined in rat thoracic aorta and tail arteries. In thoracic aorta, chloroethylclonidine (CEC), which alkylates the alpha(1B) and alpha(1D) subtypes, shifted the concentration-response curve for phenylephrine substantially to the right without reduction in maximum contraction. The pA(2) value (7.8) for 5-methylurapidil was consistent with the values reported for alpha(1D) subtype, but was higher than those in tissues in which the alpha(1B) subtype is dominant. In tail arteries, CEC did not shift the concentration-response curve for phenylephrine, but somewhat inhibited the maximum contraction. Schild analysis for 5-methylurapidil yielded a straight line with a slope significantly less than unity. Prazosin antagonized phenylephrine-induced contraction of tail arteries in a competitive manner with a pA(2) value of 8.5, consistent with values for alpha(1L) subtype. Clonidine relaxed the active tone induced by phenylephrine in both thoracic aorta and tail arteries, but quite different responses to clonidine by the two tissues were observed. After pretreatment with CEC, the relaxation induced by clonidine was abolished in thoracic aorta, but not in tail arteries. These results suggest that alpha(1D)-and alpha(1L)-adrenoceptors are mainly present in thoracic aorta and tail arteries, respectively. This difference in the populations of alpha(1)-adrenoceptor subtypes may be related to regional differences in the modes of relaxant action of clonidine.
引用
收藏
页码:31 / 42
页数:12
相关论文
共 50 条
  • [21] SYSTEMIC AND REGIONAL HEMODYNAMIC CHARACTERIZATION OF ALPHA-1 AND ALPHA-2 ADRENOCEPTOR AGONISTS IN PITHED RATS
    RICHER, C
    LEFEVREBORG, F
    LECHAIRE, J
    GOMENI, C
    GOMENI, R
    GIUDICELLI, JF
    CAVERO, I
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1987, 240 (03): : 944 - 953
  • [22] CHIRALITY IN ALPHA-ADRENOCEPTOR AND BETA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS
    RUFFOLO, RR
    TETRAHEDRON, 1991, 47 (48) : 9953 - 9980
  • [23] DOMINANT ANTAGONISTIC ACTION OF ALPHA-2-ADRENOCEPTOR AGONISTS ON ALPHA-1-AGONIST-INDUCED VASOCONSTRICTION
    SKRBIC, R
    CHIBA, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 230 (02) : 131 - 137
  • [24] SELECTIVITY OF THE IMIDAZOLINE ALPHA-ADRENOCEPTOR AGONISTS (OXYMETAZOLINE AND CIRAZOLINE) FOR HUMAN CLONED ALPHA(1)-ADRENOCEPTOR SUBTYPES
    HORIE, K
    OBIKA, K
    FOGLAR, R
    TSUJIMOTO, G
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (01) : 1611 - 1618
  • [25] THE EFFECTS OF SELECTIVE ALPHA-1-ADRENOCEPTOR AND ALPHA-2-ADRENOCEPTOR AGONISTS ON THE CORONARY RESISTANCE DISTAL TO SEVERE STENOSES
    DEUSSEN, A
    HEUSCH, G
    THAMER, V
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1984, 402 : R19 - R19
  • [26] Alpha-2 adrenoceptor agonists and sepsis: improved survival?
    Luc Quintin
    Critical Care, 14 (4):
  • [27] OVERVIEW OF ALPHA-2-ADRENOCEPTOR AGONISTS WITH A CENTRAL ACTION
    VANZWIETEN, PA
    AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (09): : E3 - E5
  • [28] Alpha-2 adrenoceptor agonists for the treatment of pain.
    Reitz, AB
    Carson, JR
    Boyd, RE
    Pitis, PM
    Jetter, MC
    Baxter, EW
    McDonnell, ME
    Ross, TM
    Connelly, CD
    Lewis, M
    Codd, EE
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U1202 - U1202
  • [29] CAMP ACCUMULATION IN RAT PROXIMAL TUBULES AND ITS FUNCTIONAL ANTAGONISM BY ALPHA-2-ADRENOCEPTOR (ALPHA-2-A) AGONISTS
    WOLFF, DW
    HICKMAN, TI
    AWAD, HG
    FALLET, RW
    PETTINGER, WA
    FASEB JOURNAL, 1991, 5 (05): : A1109 - A1109
  • [30] ACTION OF OPIOID-ADRENOCEPTOR AND ALPHA-ADRENOCEPTOR AGONISTS ON NEUROGENIC EDEMA
    LEW, R
    BENTLEY, GA
    COPELAND, IW
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1983, 10 (06) : 703 - 703